Вилазодон: механизм действия и побочные эффекты

Vilazodone is the first approved drug that is both a combination selective serotonin reuptake inhibitor (SSRI) and a partial agonist of serotonergic (5HT1A) receptors. Its mechanism of action "is not fully understood but is thought to be related to its enhancement of serotonergic activity in the central nervous system through selective inhibition of serotonin reuptake," according to a press release from Clinical Data, which holds worldwide marketing rights for the drug.

In 2 randomized, double-blind trials in adults with MDD, vilazodone 40 mg once daily was shown to be significantly superior to placebo at improving depressive symptoms, as measured by a mean change in the Montgomery-Asberg Depression Rating Scale total score from baseline to week 8. Patients in the study were titrated up to the 40-mg dose over the course of 2 weeks.

In safety studies involving 2177 patients diagnosed with MDD, the most common adverse events were diarrhea, nausea, vomiting, and insomnia. In all, 7.1% of patients who received vilazodone discontinued treatment because of an adverse reaction compared with 3.2% of control patients. The drug was not associated with change in body weight over 8 weeks, and there were no reported drug-related abnormalities in hepatic or cardiac parameters or vital signs, the company says.